|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/25/20 Aclaris Therapeutics, Inc. 10-K 12/31/19 103:13M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.65M
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 44K
3: EX-10.14 Material Contract HTML 34K
4: EX-10.15 Material Contract HTML 34K
5: EX-10.20 Material Contract HTML 108K
6: EX-21.1 Subsidiaries List HTML 29K
7: EX-23.1 Consent of Experts or Counsel HTML 28K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 33K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 32K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 33K
56: R1 Document and Entity Information HTML 64K
90: R2 Consolidated Balance Sheets HTML 131K
80: R3 Consolidated Balance Sheets (Parenthetical) HTML 46K
22: R4 Consolidated Statements of Operations and HTML 99K
Comprehensive Loss
57: R5 Consolidated Statements of Operations and HTML 30K
Comprehensive Loss (Parenthetical)
91: R6 Consolidated Statements of Stockholders' Equity HTML 89K
81: R7 Consolidated Statements of Stockholders' Equity HTML 33K
(Parenthetical)
23: R8 Consolidated Statements of Cash Flows HTML 133K
55: R9 Organization and Nature of Business HTML 41K
64: R10 Summary of Significant Accounting Policies HTML 112K
95: R11 Rhofade HTML 43K
39: R12 Fair Value of Financial Assets and Liabilities HTML 221K
28: R13 Property and Equipment, Net HTML 61K
65: R14 Intangible Assets HTML 82K
96: R15 Accrued Expenses HTML 49K
40: R16 Debt HTML 32K
29: R17 Stockholders' Equity HTML 38K
66: R18 Stock-Based Awards HTML 220K
94: R19 Net Loss per Share HTML 74K
59: R20 Leases HTML 142K
24: R21 Income Taxes HTML 185K
78: R22 Related Party Transactions HTML 40K
87: R23 Agreements Related to Intellectual Property HTML 52K
60: R24 Retirement Savings Plan HTML 32K
25: R25 Restructuring Charges HTML 32K
79: R26 Discontinued Operations HTML 190K
88: R27 Segment Information HTML 172K
58: R28 Legal Proceedings HTML 43K
26: R29 Summary of Significant Accounting Policies HTML 178K
(Policies)
32: R30 Rhofade (Tables) HTML 37K
42: R31 Fair Value of Financial Assets and Liabilities HTML 218K
(Tables)
93: R32 Property and Equipment, Net (Tables) HTML 60K
62: R33 Intangible Assets (Tables) HTML 83K
31: R34 Accrued Expenses (Tables) HTML 49K
41: R35 Stock-Based Awards (Tables) HTML 218K
92: R36 Net Loss per Share (Tables) HTML 75K
61: R37 Leases (Tables) HTML 140K
30: R38 Income Taxes (Tables) HTML 179K
43: R39 Discontinued Operations (Tables) HTML 192K
19: R40 Segment Information (Tables) HTML 170K
51: R41 Organization and Nature of Business (Details) HTML 33K
86: R42 Summary of Significant Accounting Policies HTML 51K
(Details)
77: R43 Summary of Significant Accounting Policies - HTML 36K
Property and Equipment (Details)
18: R44 Summary of Significant Accounting Policies - HTML 31K
Intangible Assets (Details)
50: R45 Summary of Significant Accounting Policies - HTML 35K
Goodwill (Details)
85: R46 Summary of Significant Accounting Policies - HTML 29K
Stock-Based Compensation (Details)
76: R47 Summary of Significant Accounting Policies - HTML 29K
Segments (Details)
17: R48 Summary of Significant Accounting Policies - HTML 34K
Recent Pronouncements (Details)
52: R49 RHOFADE - Amount Paid for Assets Acquired HTML 43K
(Details)
45: R50 RHOFADE - Summary of Fair Value Assets Acquired HTML 42K
(Details)
33: R51 Fair Value of Financial Assets and Liabilities HTML 66K
(Details)
71: R52 Fair Value of Financial Assets and Liabilities - HTML 49K
By Type (Details)
102: R53 Property and Equipment, Net (Details) HTML 53K
46: R54 Intangible Assets (Details) HTML 47K
34: R55 Intangible Assets - Future Amortization Expenses HTML 50K
(Details)
72: R56 Accrued Expenses (Details) HTML 41K
103: R57 Debt (Details) HTML 48K
44: R58 Stockholders' Equity (Details) HTML 41K
35: R59 Stockholders' Equity - Other Offerings (Details) HTML 55K
73: R60 Stock-Based Awards (Details) HTML 73K
83: R61 Stock-Based Awards - Option Activity (Details) HTML 89K
53: R62 Stock-Based Awards - RSUs (Details) HTML 54K
20: R63 Stock-Based Awards - Compensation (Details) HTML 50K
74: R64 Net Loss per Share (Details) HTML 38K
84: R65 Net Loss per Share - Anti-dilution (Details) HTML 36K
54: R66 Leases - Lease Costs (Details) HTML 37K
21: R67 Leases (Details) HTML 70K
75: R68 Leases - Finance Leases (Details) HTML 53K
82: R69 Leases - Supplemental Information Related to HTML 48K
Operating and Finance Leases (Details)
99: R70 Leases - Future Maturities of Lease Liabilities HTML 56K
(Details)
69: R71 Income Taxes - Tax Cuts and Jobs Act (Details) HTML 42K
37: R72 Income Taxes - Rate Reconciliation (Details) HTML 74K
48: R73 Income Taxes - Deferred Assets and Liabilities, HTML 89K
CFDs (Details)
98: R74 Income Taxes - Valuation Allowance and HTML 49K
Unrecognized Tax Benefits (Details)
68: R75 Related Party Transactions (Details) HTML 50K
36: R76 Agreements Related to Intellectual Property HTML 121K
(Details)
47: R77 Retirement Savings Plan (Details) HTML 33K
101: R78 Restructuring Charges (Details) HTML 49K
67: R79 Discontinued Operations - Loss (Details) HTML 67K
100: R80 Discontinued Operations - Assets and Liabilities HTML 83K
(Details)
70: R81 Discontinued Operations - Cash Flow (Details) HTML 44K
38: R82 Discontinued Operations (Details) HTML 38K
49: R83 Segment Information (Details) HTML 68K
97: R84 Legal Proceedings (Details) HTML 29K
89: XML IDEA XML File -- Filing Summary XML 181K
63: EXCEL IDEA Workbook of Financial Reports XLSX 116K
11: EX-101.INS XBRL Instance -- acrs-20191231 XML 3.40M
13: EX-101.CAL XBRL Calculations -- acrs-20191231_cal XML 261K
14: EX-101.DEF XBRL Definitions -- acrs-20191231_def XML 718K
15: EX-101.LAB XBRL Labels -- acrs-20191231_lab XML 1.80M
16: EX-101.PRE XBRL Presentations -- acrs-20191231_pre XML 1.22M
12: EX-101.SCH XBRL Schema -- acrs-20191231 XSD 218K
27: ZIP XBRL Zipped Folder -- 0001558370-20-001325-xbrl Zip 244K
| acrs_Ex10_14 |
Exhibit 10.14
ACLARIS THERAPEUTICS, INC.
SECOND AMENDED & RESTATED
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Aclaris Therapeutics, Inc. (the “Company”) or any of its affiliates or NeXeption, LLC or any affiliates of NeXeption, LLC (each such member, an “Eligible Director”) will receive the compensation described in this Second Amended & Restated Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service effective as of October 30, 2019 (the “Effective Date”). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be. This Policy may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board. The terms and conditions of this Policy shall supersede any prior Non-Employee Director Compensation Policy of the Company.
Annual Cash Compensation
The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment.
1. Annual Board Service Retainer:
a. All Eligible Directors: $40,000
2. Annual Committee Member Service Retainer:
a. Member of the Audit Committee: $7,500
b. Member of the Compensation Committee: $6,000
c. Member of the Nominating and Corporate Governance Committee: $4,500
3. Annual Committee Chair Service Retainer (in addition to Committee Member Service Retainer):
a. Chairman of the Audit Committee: $12,500
b. Chairman of the Compensation Committee: $8,000
c. Chairman of the Nominating and Corporate Governance Committee: $4,500
4. Annual Chairman of the Board Service Retainer (in addition to Board Service Retainer): $27,500
Equity Compensation
The equity compensation set forth below will be granted under the Company’s 2015 Equity Incentive Plan (the “Plan”). All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the Company’s underlying common stock (the “Common Stock”) on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).
1. Initial Grant: On the date of the Eligible Director’s initial election to the Board, for each Eligible Director who is first elected to the Board following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option to purchase 22,000 shares of the Company’s Common Stock, with an exercise price per share equal to 100% of the Fair Market Value of the Company’s Common Stock on the date of grant. The shares subject to each such stock option will vest in equal monthly
installments for 36 months, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date[s].
2. Annual Grant: On the date of each annual stockholders meeting of the Company held on and after the Effective Date, each Eligible Director who continues to serve as a non-employee member of the Board following such stockholders meeting will be automatically, and without further action by the Board or Compensation Committee of the Board, granted (a) a stock option to purchase 11,000 shares of the Company’s Common Stock, with an exercise price per share equal to 100% of the Fair Market Value of the Company’s Common Stock on the date of grant or (b) if approved by the Board or the Compensation Committee of the Board prior to any such meeting, a number of restricted stock units at a ratio to the number of shares such Eligible Director would have received under clause (a) as determined by the Board or the Compensation Committee (or any combination of clause (a) and this clause (b)). The shares subject to each such stock option will vest in equal monthly installments for 12 months and the restricted stock units will vest in one installment on the first anniversary of the grant date, subject to the Eligible Director’s Continuous Service through such vesting date[s].
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/25/20 | 8-K | ||
| For Period end: | 12/31/19 | |||
| 10/30/19 | 4 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/25/21 Aclaris Therapeutics, Inc. 10-K 12/31/20 104:12M Toppan Merrill Bridge/FA 1/20/21 Aclaris Therapeutics, Inc. 424B5 1:650K Toppan Merrill/FA 1/19/21 Aclaris Therapeutics, Inc. 424B5 1:652K Toppan Merrill/FA 8/13/20 Aclaris Therapeutics, Inc. 424B5 1:495K Toppan Merrill/FA |